Size or Shape? The Never-Ending Fairytale of Melanocortin Peptides

Melanocortin peptides represent an exemplary model for investigating the relationship between the structure and function of G protein-coupled receptor (GPCR) ligands. Following the identification of the minimal pharmacophore sequence His-Phe-Arg-Trp within α-melanocyte-stimulating hormone (α-MSH), considerable efforts have been devoted to enhancing peptide stability, potency, and receptor selectivity across melanocortin receptor (MC) subtypes.

The development of cyclic analogs, such as MTII, has highlighted the significance of conformational constraints in enhancing biological activity, supporting the notion that ligand conformation is a primary determinant of receptor interactions. However, the discovery of SHU9119, where a single substitution (DPhe to DNal(2’)) results in a transition from agonist to antagonist activity at MC3 and MC4 receptors, has challenged this paradigm and raised fundamental questions regarding the interplay between steric factors and conformational effects in peptide ligands. Building on these foundational studies, our research focused on the rational design of novel melanocortin ligands targeting hMC3, hMC4, and hMC5 receptors.

By systematically modulating the peptide size, backbone flexibility, and side-chain properties, we aimed to elucidate the relative contributions of molecular size and three-dimensional shape to receptor selectivity and functional activity. Our findings suggest that neither size nor shape alone can fully account for the observed pharmacological profile. Instead, receptor selectivity emerges from a nuanced interplay between these parameters, where even subtle structural modifications can induce significant changes in ligand behavior.

This ongoing investigation underscores the complexity of melanocortin ligand design and highlights the necessity of integrated structure-based approaches for developing selective, functionally tuned GPCR modulators.